Produção Nacional
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data
2022; BioMed Central; Volume: 62; Issue: 1 Linguagem: Inglês
10.1186/s42358-022-00268-x
ISSN2523-3106
AutoresCláudia Diniz Lopes Marques, Sandra Lúcia Euzébio Ribeiro, Cleandro Pires de Albuquerque, Sâmia Araújo de Sousa Studart, Aline Ranzolin, Nicole Pamplona Bueno de Andrade, Andréa Tavares Dantas, G.D. Mota, Gustavo Gomes Resende, Adriana O. Marinho, Danielle Angelieri, Danieli Andrade, Francinne Machado Ribeiro, Felipe Omura, Nilzio A. Silva, Laurindo Ferreira da Rocha, Danielle E. Brito, Diana Campos Fernandino, Michel Alexandre Yazbek, Mariana Peixoto Guimarães Ubirajara e Silva de Souza, Antônio Carlos Ximenes, Ana Silvia S. Martins, Gláucio Ricardo Werner de Castro, Lívia Carlos Fernandes de Oliveira, Ana Beatriz Santos Bacchiega de Freitas, Adriana María Kakehasi, Ana Paula Monteiro Gomides, E.T. Reis Neto, Gecilmara Salviato Pileggi, Gilda Aparecida Ferreira, Lícia Maria Henrique da Mota, Ricardo Machado Xavier, Marcelo Antônio Amaro Pinheiro,
Tópico(s)Bone and Joint Diseases
ResumoAbstract Objectives To evaluate the disease activity before and after COVID-19 and risk factors associated with outcomes, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation (MV) and death in patients with spondylarthritis (SpA). Methods ReumaCoV Brazil is a multicenter prospective cohort of immune-mediated rheumatic diseases (IMRD) patients with COVID-19 (case group), compared to a control group of IMRD patients without COVID-19. SpA patients enrolled were grouped as axial SpA (axSpA), psoriatic arthritis (PsA) and enteropathic arthritis, according to usual classification criteria. Results 353 SpA patients were included, of whom 229 (64.9%) were axSpA, 118 (33.4%) PsA and 6 enteropathic arthritis (1.7%). No significant difference was observed in disease activity before the study inclusion comparing cases and controls, as well no worsening of disease activity after COVID-19. The risk factors associated with hospitalization were age over 60 years (OR = 3.71; 95% CI 1.62–8.47, p = 0.001); one or more comorbidities (OR = 2.28; 95% CI 1.02–5.08, p = 0.001) and leflunomide treatment (OR = 4.46; 95% CI 1.33–24.9, p = 0.008). Not having comorbidities (OR = 0.11; 95% CI 0.02–0.50, p = 0.001) played a protective role for hospitalization. In multivariate analysis, leflunomide treatment (OR = 8.69; CI = 95% 1.41–53.64; p = 0.023) was associated with hospitalization; teleconsultation (OR = 0.14; CI = 95% 0.03–0.71; p = 0.01) and no comorbidities (OR = 0.14; CI = 95% 0.02–0.76; p = 0.02) remained at final model as protective factor. Conclusions Our results showed no association between pre-COVID disease activity or that SARS-CoV-2 infection could trigger disease activity in patients with SpA. Teleconsultation and no comorbidities were associated with a lower hospitalization risk. Leflunomide remained significantly associated with higher risk of hospitalization after multiple adjustments.
Referência(s)